Literature DB >> 16097054

Sonographic fatty liver, overweight and ischemic heart disease.

Yu-Cheng Lin1, Huey-Ming Lo, Jong-Dar Chen.   

Abstract

AIM: To demonstrate the prevalence of sonographic fatty liver, overweight and ischemic heart disease (IHD) among the male workers in Taiwan, and to investigate the possible association of these three factors.
METHODS: From July to September 2003, a total of 2 088 male aircraft-maintenance workers aged from 22 to 65 years (mean 40.5) underwent an annual health examination, including anthropometrical evaluation, blood pressure measurement, personal medical history assessment, biochemical blood analysis, abdominal ultrasonographic examination and digital electrocardiography (ECG). The Student's t-test, chi(2) test and multivariate logistic regression analysis were utilized to evaluate the relationship between IHD and salient risk factors.
RESULTS: The all-over prevalence of overweight was 41.4%, and that of fatty liver was 29.5% (mild, moderate and severe fatty liver being 14.5%, 11.3%, and 3.7%, respectively); while the prevalence of ischemic changes on ECG was 17.1% in this study. The abnormal rates for conventional IHD risk factors including hypertension, dyslipidemia, hyperglycemia and overweight increased in accordance with the severity of fatty liver. Overweight and severity of fatty liver were independently associated with increased risks for developing IHD. Overweight subjects had a 1.32-fold (95%CI: 1.01-1.73) increased IHD risk. Participants with mild, moderate, and severe fatty liver had a 1.88-fold (95%CI: 1.37-2.6), 2.37-fold (95%CI: 1.66-3.37) and 2.76-fold (95%CI: 1.62-4.72) increased risk for developing IHD. The prevalence of ischemic ECG for the fatty liver-affected subjects with or without overweight was 30.1% and 19.1%, while that of overweight subjects free from fatty liver was 14.4%. Compared to the subjects without fatty liver nor overweight, IHD risk for the three subgroups above was as follows: OR: 2.95 (95%CI: 2.31-4.09), OR: 1.60 (95%CI: 1.07-2.39) and OR: 1.11 (95%CI: 0.78-1.56), respectively.
CONCLUSION: The presence of fatty liver and its severity should be carefully considered as independent risk factors for IHD. Results of the study suggest the synergistic effect between fatty liver and overweight for developing IHD. Abdominal sonographic examination may provide valuable information for IHD risk assessment in addition to limited report about liver status, especially for overweight males.

Entities:  

Mesh:

Year:  2005        PMID: 16097054      PMCID: PMC4398732          DOI: 10.3748/wjg.v11.i31.4838

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  Abdominal sonographic screening in a single community.

Authors:  S N Lu; L Y Wang; W Y Chang; C J Chen; W P Su; S C Chen; W L Chuang; M Y Hsieh
Journal:  Gaoxiong Yi Xue Ke Xue Za Zhi       Date:  1990-12

Review 2.  Pathophysiology and treatment of the dyslipidemia of insulin resistance.

Authors:  G Cohn; G Valdes; D M Capuzzi
Journal:  Curr Cardiol Rep       Date:  2001-09       Impact factor: 2.931

3.  Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan.

Authors:  M Akahoshi; Y Amasaki; M Soda; T Tominaga; S Ichimaru; E Nakashima; S Seto; K Yano
Journal:  Hypertens Res       Date:  2001-07       Impact factor: 3.872

4.  Computerized ST depression analysis improves prediction of all-cause and cardiovascular mortality: the strong heart study.

Authors:  P M Okin; R B Devereux; J A Kors; G van Herpen; R S Crow; R R Fabsitz; B V Howard
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-04       Impact factor: 1.468

5.  Distribution and correlates of lipids and lipoproteins in elderly Japanese-American men. The Honolulu Heart Program.

Authors:  C M Burchfiel; R D Abbott; D S Sharp; J D Curb; B L Rodriguez; K Yano
Journal:  Arterioscler Thromb Vasc Biol       Date:  1996-11       Impact factor: 8.311

6.  Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study.

Authors:  B Lamarche; J P Després; S Moorjani; B Cantin; G R Dagenais; P J Lupien
Journal:  Atherosclerosis       Date:  1996-01-26       Impact factor: 5.162

Review 7.  Insulin resistance and endothelial dysfunction in atherosclerosis: implications and interventions.

Authors:  Paresh Dandona
Journal:  Diabetes Technol Ther       Date:  2002       Impact factor: 6.118

8.  Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men.

Authors:  Seung Ha Park; Byung Ik Kim; Jung Won Yun; Jeong Wook Kim; Dong Il Park; Yong Kyun Cho; In Kyung Sung; Chang Young Park; Chong Il Sohn; Woo Kyu Jeon; Hyang Kim; Eun Jung Rhee; Won Young Lee; Sun Woo Kim
Journal:  J Gastroenterol Hepatol       Date:  2004-06       Impact factor: 4.029

9.  [Accuracy of sonography in the diagnosis of diffuse liver parenchymal diseases--comparison of sonography and liver histology].

Authors:  H J Steinmaurer; P Jirak; J Walchshofer; P H Clodi
Journal:  Ultraschall Med       Date:  1984-06       Impact factor: 6.548

Review 10.  Metabolic complications of obesity.

Authors:  S M Grundy
Journal:  Endocrine       Date:  2000-10       Impact factor: 3.925

View more
  37 in total

1.  Preclinical cardiac disease in nonalcoholic fatty liver disease with and without metabolic syndrome.

Authors:  Jasbir Makker; Hassan Tariq; Jonathan N Bella; Kishore Kumar; Chukwunonso Chime; Harish Patel; Muhammad Umar Kamal; Danial Shaikh; Vamshidhar Vootla; Bharat Bajantri; Umut Gomceli; Mohammad Alshelleh; Richard Peralta; Aiyi Zhang; Sridhar Chilimuri
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

Review 2.  Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis.

Authors:  Luan Rodrigues Abdallah; Ricardo Cardoso de Matos; Yves Pacheco Dias March E Souza; Débora Vieira-Soares; Gabriela Muller-Machado; Priscila Pollo-Flores
Journal:  Curr Atheroscler Rep       Date:  2020-02-04       Impact factor: 5.113

3.  Ultrasound Diagnosis of Hepatic Steatosis as a Surrogate for Atherosclerosis.

Authors:  S Guth; E Windler; U Leise; C M Bamberger
Journal:  Ultrasound Int Open       Date:  2016-03-01

Review 4.  Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.

Authors:  Alexandra Jichitu; Simona Bungau; Ana Maria Alexandra Stanescu; Cosmin Mihai Vesa; Mirela Marioara Toma; Cristiana Bustea; Stela Iurciuc; Marius Rus; Nicolae Bacalbasa; Camelia Cristina Diaconu
Journal:  Diagnostics (Basel)       Date:  2021-04-12

Review 5.  Nonalcoholic fatty liver disease: implications for cardiovascular risk.

Authors:  Amreen Dinani; Arun Sanyal
Journal:  Cardiovasc Endocrinol       Date:  2017-05-17

Review 6.  Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk.

Authors:  Lucia Pacifico; Valerio Nobili; Caterina Anania; Paola Verdecchia; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

Review 7.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 8.  Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?

Authors:  G Targher; F Marra; G Marchesini
Journal:  Diabetologia       Date:  2008-09-02       Impact factor: 10.122

9.  The Risk of Cardiovascular Disease, Diabetes, Liver-Related Outcomes, and Death Over 10 Years in HIV/HCV-Coinfected Patients With and Without Steatosis.

Authors:  Carrie Down; Natasha Mehta; Kristen Marks
Journal:  AIDS Res Hum Retroviruses       Date:  2016-06-21       Impact factor: 2.205

10.  Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.

Authors:  Winston Dunn; Ronghui Xu; Deborah L Wingard; Christopher Rogers; Paul Angulo; Zobair M Younossi; Jeffrey B Schwimmer
Journal:  Am J Gastroenterol       Date:  2008-08-05       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.